Cargando…

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)

PURPOSE OF REVIEW: The aim of low-density lipoprotein-cholesterol (LDL-C) lowering therapies is to safely achieve a consistent and long-term reduction in exposure of the vasculature to atherogenic lipoproteins in order to reduce the risk of atherosclerotic cardiovascular (CV) disease and the associa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sinning, David, Landmesser, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	New Therapies for Cardiovascular Disease (AA Bavry, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578129/ https://www.ncbi.nlm.nih.gov/pubmed/33089390 http://dx.doi.org/10.1007/s11886-020-01427-6

Ejemplares similares

ACURATE neo: How Is This TAVR Valve Doing to Fit into an Increasingly Crowded Field?
por: Okuno, Taishi, et al.
Publicado: (2020)

Drug-coated Balloons for Small Coronary Disease—A Literature Review
por: Arslani, Ketina, et al.
Publicado: (2021)

The New Role of Telehealth in Contemporary Medicine
por: Randall, Morgan H., et al.
Publicado: (2022)

Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis
por: Wang, Tom Kai Ming, et al.
Publicado: (2022)

A Clinician’s Guide to Smartwatch “Interrogation”
por: Gupta, Shishir, et al.
Publicado: (2022)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Inclisiran: a new generation of lipid-lowering siRNA therapeutic
por: Zhang, Yanzhen, et al.
Publicado: (2023)

Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia
por: Ebenezer, Oluwakemi, et al.
Publicado: (2023)

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
por: Arnold, Natalie, et al.
Publicado: (2022)

Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis
por: Desai, Nihar R., et al.
Publicado: (2022)

Cohort profile: role of lipoproteins in cardiovascular disease—the LipidCardio study
por: König, Maximilian, et al.
Publicado: (2019)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Effects of Apolipoprotein A-I/High-Density Lipoprotein Cholesterol on Atherosclerotic Vascular Disease: Critical Impact of Atherosclerosis Disease Stage and Disease Milieu?
por: Haghikia, Arash, et al.
Publicado: (2018)

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis
por: Kong, Ni, et al.
Publicado: (2022)

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Anti‐PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
por: Descamps, Olivier S., et al.
Publicado: (2017)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
por: Makhmudova, U., et al.
Publicado: (2023)

Sepsis-Induced Cardiomyopathy: a Comprehensive Review
por: L’Heureux, Michael, et al.
Publicado: (2020)

Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and Treatment
por: Bruestle, Karina, et al.
Publicado: (2020)

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
por: Nissen, Steven E, et al.
Publicado: (2022)

Inclisiran—A Revolutionary Addition to a Cholesterol-Lowering Therapy
por: Dec, Adrianna, et al.
Publicado: (2023)

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
por: Ray, Kausik K, et al.
Publicado: (2022)

Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
por: Puccini, Marianna, et al.
Publicado: (2022)

Lipid lowering with inclisiran: a real-world single-centre experience
por: Padam, Pritpal, et al.
Publicado: (2022)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
por: Ference, Brian A, et al.
Publicado: (2018)

Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe
por: Cheng, Yinchu, et al.
Publicado: (2022)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Inclisiran for the treatment of hypercholesterolaemia: implications and unanswered questions from the ORION trials
por: Cupido, Arjen J, et al.
Publicado: (2020)

Cumulative non-high-density lipoprotein cholesterol burden and risk of atherosclerotic cardiovascular disease: a prospective community-based study
por: Guan, Xu-Min, et al.
Publicado: (2023)

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease
por: Albosta, Michael S, et al.
Publicado: (2023)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Inclisiran: How Widely and When Should We Use It?
por: Pirillo, Angela, et al.
Publicado: (2022)

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
por: Ray, Kausik K, et al.
Publicado: (2022)

The formation and consequences of cholesterol-rich deposits in atherosclerotic lesions
por: Maxfield, Frederick R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_asp8iampl45mpdrddome3crekl